{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-25-009701","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2025-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.803576+00:00","generated_at":"2026-05-17T21:53:04.490280+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Amneal completes $2.7B refinancing: $2.1B term loan and $600M notes","bullets":["Borrowed $2.1B of new seven-year term B loans due Aug 2032; margin SOFR+3.50% or base+2.50%.","Issued $600M 6.875% senior secured notes due Aug 2032; proceeds used to refinance existing debt.","Amended ABL facility extends maturity to Aug 2030; $600M revolving commitments unchanged.","Refinanced existing $2.26B term loans in full and repaid all ABL borrowings with net proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-25-009701","json":"https://secwatch.observer/filing/0000950103-25-009701.json","markdown":"https://secwatch.observer/filing/0000950103-25-009701.md","text":"https://secwatch.observer/filing/0000950103-25-009701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/0000950103-25-009701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/dp232462_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:53:04.490280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1fe0cc6d2a5f258cabaab72fb34b17b4f505c121","claim":"Amneal Pharmaceuticals, Inc. incurred senior notes of $600 million aggregate principal amount with Wilmington Savings Fund Society, FSB, as trustee and collateral agent at 6.875% maturing August 1, 2032.","evidence_excerpt":"completed the previously announced offering of $600 million aggregate principal amount of 6.875% senior secured notes due 2032 (the “Notes”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/0000950103-25-009701-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$600 million aggregate principal amount"},{"label":"Counterparty","value":"Wilmington Savings Fund Society, FSB, as trustee and collateral agent"},{"label":"Rate","value":"6.875%"},{"label":"Maturity","value":"August 1, 2032"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"dbeb505f778db447d23900139551809cba6aa10b","claim":"Amneal Pharmaceuticals, Inc. incurred term loan of $2.1 billion with JPMorgan Chase Bank, N.A., as administrative agent at term SOFR benchmark rate or the base rate, plus an applicable margin, ... subjec maturing August 1, 2032.","evidence_excerpt":"On August 1, 2025, Amneal Pharmaceuticals, Inc.’s (the “Corporation”) subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Issuer”) borrowed $2.1 billion of new seven-year term B loans (the “New Term Loan”) pursuant to an amendment to the Company’s existing term loan credit facility","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000095010325009701/0000950103-25-009701-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$2.1 billion"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A., as administrative agent"},{"label":"Rate","value":"term SOFR benchmark rate or the base rate, plus an applicable margin, ... subjec"},{"label":"Maturity","value":"August 1, 2032"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}